Table 2.

 Total burden of invasive pneumococcal disease (IPD) due to vaccine serotype (undiscounted) over nine year period (2012-13 to 2020-21) in people at high risk

Variables	Cases of IPD due to vaccine serotypes	Deaths	Life years	QALYs
Without high risk vaccination and without herd protection benefits of 13 valent pneumococcal conjugate vaccine*	7522	1895	34 251	36 579
Cases prevented by herd effects of infant 13 valent pneumococcal conjugate vaccine programme†	6189	1538	28 397	30 382
Without high risk vaccination and with herd effects of additional six serotypes in 13 valent pneumococcal conjugate vaccine	1333	357	5854	6197
With high risk group vaccination (including herd effects of infant programme)‡	927	247	4033	4274
Averted burden by high risk vaccination (incremental effects)§	406	110	1821	1923

QALYs=quality adjusted life years.

*Only including herd effect due to serotypes included in seven valent pneumococcal conjugate vaccine (excluding herd effect due to six additional serotypes included in 13 valent pneumococcal conjugate vaccine.

†Herd effects due to additional six serotypes in 13 valent pneumococcal conjugate vaccine based on incidence after vaccination with seven valent pneumococcal conjugate vaccine (see methods and appendix 2 in supplementary file).

‡Vaccination uptake to be assumed similar to that of annual influenza uptake (see methods).

§Numbers may not add up owing to rounding.